Morphological and immunohistochemical studies are essential and usually sufficient to differentiating metastases from primary pituitary adenomas, with markers such as PSMA, P501s, PHAP, and prostate-specific antigen (PSA) helping to confirm a prostatic origin of the metastatic lesion. The gene discussed is FOLH1; the disease is pituitary gland adenoma.